Valuation: CROSSJECT

Market Cap 99.74M 114M 91.94M 86.07M 161M 10.73B 165M 1.11B 428M 5.3B 427M 418M 18.39B P/E 2026 *
4.47x
P/E 2027 * 3.52x
Enterprise Value 81.84M 93.34M 75.44M 70.63M 132M 8.81B 135M 907M 351M 4.35B 350M 343M 15.09B EV / Sales 2026 *
1.35x
EV / Sales 2027 * 1.25x
Free-Float
89.86%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 63 08/08/2001
Director of Finance/CFO - 25/03/2026
Corporate Officer/Principal - 20/08/2024
Director TitleAgeSince
Chairman 67 26/06/2009
Director/Board Member 67 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+1.97%+2.22%-20.19%-70.27% 83.27M
+0.83%-6.39%+74.29%-2.14% 69.08M
Average +1.22%-3.46%+27.05%-36.21% 76.18M
Weighted average by Cap. +1.25%-3.11%+22.65%-39.38%

Financials

2026 *2027 *
Net sales 60.8M 69.34M 56.04M 52.47M 98.39M 6.54B 100M 674M 261M 3.23B 260M 255M 11.21B 42.3M 48.24M 38.99M 36.5M 68.45M 4.55B 69.87M 469M 181M 2.25B 181M 177M 7.8B
Net income 28.3M 32.28M 26.09M 24.42M 45.8M 3.04B 46.75M 314M 121M 1.5B 121M 119M 5.22B 7.75M 8.84M 7.14M 6.69M 12.54M 834M 12.8M 85.86M 33.22M 412M 33.19M 32.47M 1.43B
Net Debt -17.9M -20.42M -16.5M -15.45M -28.97M -1.93B -29.57M -198M -76.74M -952M -76.66M -74.98M -3.3B -47M -53.6M -43.32M -40.56M -76.06M -5.06B -77.63M -521M -201M -2.5B -201M -197M -8.67B
Logo CROSSJECT
Crossject specializes in manufacturing and marketing needleless drug self-injection. The group provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-